跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 808 条关于
“POZ-VMAT2i”
全部
808
临床试验
625
药物
121
机构
16
资讯
46
去年
Serina Therapeutics Advances Once-Weekly Injectable VMAT2 Inhibitor for Tardive Dyskinesia Treatment
9个月前
Serina Therapeutics Responds to FDA Clinical Hold on SER-252 Parkinson's Disease Treatment
去年
Serina Therapeutics' SER-252 to Enter Clinical Trials for Advanced Parkinson's Disease
去年
Serina Therapeutics Gains $10M to Advance Parkinson's Drug SER-252 into Phase 1
7个月前
Serina Therapeutics Receives FDA IND Clearance for SER-252 Parkinson's Disease Therapy
去年
Serina Therapeutics and enVVeno Medical Each File $100M Mixed Securities Shelf
去年
Neurocrine Launches Phase 1 Trial of Novel VMAT2 Inhibitor for Neurological Disorders
5年前
Luye Pharma's Next-Generation VMAT2 Inhibitor LY03015 to Begin Clinical Trials in the U.S.
8个月前
INGREZZA Demonstrates Nearly Two-Fold Higher VMAT2 Target Occupancy Than AUSTEDO XR in Head-to-Head Study
2年前
TC BioPharm to Explore Gamma Delta T-Cell Therapy TCB008 for Mpox Treatment
第 1 页,共 5 页
上一页
下一页